In vivo proton magnetic resonance spectroscopy (MRS) was first demonstrated to be feasible in vivo in the human brain in the mid-1980s , and the first example of it being applied to human brain tumors following soon after in 1989 . It was already apparent from this paper that brain tumors had greatly different metabolite profiles compared to normal tissue, and that differences in spectra may exist between different brain lesions of different pathologies. Since that time, there has been steady progress in the use of MRS and the related technique of magnetic resonance spectroscopic imaging (MRSI) for the clinical evaluation of human brain tumors .
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)